JP2016521556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521556A5 JP2016521556A5 JP2016518041A JP2016518041A JP2016521556A5 JP 2016521556 A5 JP2016521556 A5 JP 2016521556A5 JP 2016518041 A JP2016518041 A JP 2016518041A JP 2016518041 A JP2016518041 A JP 2016518041A JP 2016521556 A5 JP2016521556 A5 JP 2016521556A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleotide
- nucleotides
- composition
- stranded oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832677P | 2013-06-07 | 2013-06-07 | |
| US61/832,677 | 2013-06-07 | ||
| PCT/US2014/041345 WO2014197826A1 (en) | 2013-06-07 | 2014-06-06 | Compositions and methods for modulating foxp3 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521556A JP2016521556A (ja) | 2016-07-25 |
| JP2016521556A5 true JP2016521556A5 (enExample) | 2017-07-20 |
Family
ID=52008624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518041A Pending JP2016521556A (ja) | 2013-06-07 | 2014-06-06 | Ｆｏｘｐ３発現を調節するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160122760A1 (enExample) |
| EP (1) | EP3004354A4 (enExample) |
| JP (1) | JP2016521556A (enExample) |
| KR (1) | KR20160027968A (enExample) |
| AU (1) | AU2014274730A1 (enExample) |
| CA (1) | CA2914536A1 (enExample) |
| WO (1) | WO2014197826A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2873769A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating hemoglobin gene family expression |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| BR112014028644A2 (pt) | 2012-05-16 | 2017-08-15 | Rana Therapeutics Inc | Composições e métodos para modulação da expressão de atp2a2 |
| AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| SG11201407483YA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating smn gene family expression |
| BR112014028634A2 (pt) | 2012-05-16 | 2017-06-27 | Rana Therapeutics Inc | composições e métodos para modulação da expressão de utrn |
| JP2016531570A (ja) * | 2013-08-16 | 2016-10-13 | ラナ セラピューティクス インコーポレイテッド | ユークロマチン領域を標的とするオリゴヌクレオチド |
| AU2015228860A1 (en) * | 2014-03-13 | 2016-09-08 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
| WO2017181026A1 (en) * | 2016-04-15 | 2017-10-19 | Translate Bio Ma, Inc. | Selective modulation of foxp3 expression |
| WO2017184082A1 (en) * | 2016-04-22 | 2017-10-26 | Nanyang Technological University | A lymphocyte permeating chimeric oligonucleotide, methods and uses thereof |
| WO2018031871A1 (en) * | 2016-08-12 | 2018-02-15 | Translate Bio Ma, Inc. | Ex vivo modulation of foxp3 expression |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| WO2018102397A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US12024715B2 (en) * | 2017-11-07 | 2024-07-02 | Temple University-Of The Commonwealth System Of Higher Education | Compositions and methods for improved T cells |
| WO2020069044A1 (en) * | 2018-09-26 | 2020-04-02 | AUM LifeTech, Inc. | 2' fana modified foxp3 antisense oligonucleotides and methods of use thereof |
| TW202028222A (zh) * | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| CN111378622B (zh) * | 2018-12-29 | 2022-12-02 | 华东师范大学 | 核酸编码的car-t细胞及其制备方法和应用 |
| UY38562A (es) * | 2019-01-29 | 2020-08-31 | Ionis Pharmaceuticals Inc | Compuestos y métodos para reducir la expresión de app |
| WO2020212567A1 (en) * | 2019-04-18 | 2020-10-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of usher syndrome |
| US11866708B2 (en) * | 2019-10-22 | 2024-01-09 | Board Of Regents, The University Of Texas System | Tailored modulation of gene regulation programs via functional enhancer RNA |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| US12384814B2 (en) | 2020-07-28 | 2025-08-12 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing app expression |
| WO2022088342A1 (zh) * | 2020-10-28 | 2022-05-05 | 苏州吉玛基因股份有限公司 | 一种靶向FOXP3基因的siRNA及其修饰方法 |
| US20250188476A1 (en) * | 2021-06-18 | 2025-06-12 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ifnar1 expression |
| WO2023235838A2 (en) * | 2022-06-02 | 2023-12-07 | Skyhawk Therapeutics, Inc. | Rna-targeting splicing modifiers for treatment of foxp3-associated conditions and diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US14008A (en) * | 1856-01-01 | Improvement in furnaces for soldering | ||
| EP1967525B1 (en) * | 2001-05-08 | 2012-11-14 | Darwin Molecular Corporation | A method for regulating immune function in primates using the foxp3 protein |
| US8029985B2 (en) * | 2004-09-01 | 2011-10-04 | Vybion, Inc. | Amplified bioassay |
| US8629108B2 (en) * | 2006-06-27 | 2014-01-14 | Opexa Therapeutics, Inc. | Rheumatoid arthritis T cell vaccine |
| US8420791B2 (en) * | 2006-11-27 | 2013-04-16 | Ludwig Institute For Cancer Research Ltd. | Expression of FoxP3 by cancer cells |
| WO2008103761A2 (en) * | 2007-02-20 | 2008-08-28 | Sequenom, Inc. | Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation |
| US8158596B2 (en) * | 2007-05-11 | 2012-04-17 | The Regents Of The University Of Michigan | Materials and methods for FOXP3 tumor suppression |
| US20120004278A1 (en) * | 2010-06-18 | 2012-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Linc rnas in cancer diagnosis and treatment |
| WO2012003810A1 (zh) * | 2010-07-09 | 2012-01-12 | 中国科学院上海巴斯德研究所 | Foxp3及调节性ｔ细胞的调节因子及其应用 |
| WO2012020839A1 (ja) * | 2010-08-12 | 2012-02-16 | 塩野義製薬株式会社 | 癌治療用医薬組成物 |
| BR112013005806B1 (pt) * | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| US9920317B2 (en) * | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
| EP3511416A1 (en) * | 2012-05-16 | 2019-07-17 | Translate Bio MA, Inc. | Compositions and methods for modulating gene expression |
| EA201492117A1 (ru) * | 2012-05-16 | 2015-04-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии bdnf |
| EP2850183A4 (en) * | 2012-05-16 | 2016-02-10 | Rana Therapeutics Inc | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION |
| WO2014025887A1 (en) * | 2012-08-07 | 2014-02-13 | The General Hospital Corporation | Selective reactivation of genes on the inactive x chromosome |
-
2014
- 2014-06-06 AU AU2014274730A patent/AU2014274730A1/en not_active Abandoned
- 2014-06-06 KR KR1020167000349A patent/KR20160027968A/ko not_active Withdrawn
- 2014-06-06 CA CA2914536A patent/CA2914536A1/en not_active Abandoned
- 2014-06-06 EP EP14807355.4A patent/EP3004354A4/en not_active Withdrawn
- 2014-06-06 JP JP2016518041A patent/JP2016521556A/ja active Pending
- 2014-06-06 US US14/896,537 patent/US20160122760A1/en not_active Abandoned
- 2014-06-06 WO PCT/US2014/041345 patent/WO2014197826A1/en not_active Ceased